Albuvirtide
- Generic Name
- Albuvirtide
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1417179-66-8
- Unique Ingredient Identifier
- MG9PC54E43
- Background
Albuvirtide is under investigation in clinical trial NCT03719664 (Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects).
- Indication
适用于与其它抗反转录病毒药物联合使用，治疗已接受过抗病毒药物治疗的HIV-1感染者。
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate Pharmacokinetic and Safety of Albuvirtide Between Intravenous Drip and Intravenous Injection
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05206019
- Locations
- 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, China
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04819347
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Albuvirtide in Combination With 3BNC117 in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04560569
- Locations
- 🇺🇸
ABT-3BNC117_203 Investigational Site, Saint Louis, Missouri, United States
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT03719664
- Locations
- 🇺🇸
ABT-3BNC117_201 Investigational Site, New York, New York, United States
Test Albuvirtide in Experienced Patients
- Conditions
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 418
- Registration Number
- NCT02369965
- Locations
- 🇨🇳
The Third People'S Hospital Of Shenzhen, Shenzhen, Guangdong, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
🇨🇳Beijing Youan Hospital, Capital medical university, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.